| Pipeline | Modality | Target | Indication | Development Status | Discovery | Pre- Clinical |
Phase 1 | Phase 2a | Phase 2b | Phase 3 | Partner |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
CU06 (Rivasterat) |
PO | Endothelial Dysfunction Blocker | Diabetic macular edema / Age-related Macular Degeneration | Completed Phase 2a clinical trial in the U.S(2024.1Q) | |||||||
| CU01 | PO | NRF2 / TGF-β | Diabetic Nephropathy | Completed Phase 2b clinical trial in Korea(2026.1Q) | |||||||
| MT-101 | IV(mAb) | Tie2 | Acute Kidney Injury/ Chronic Kidney Disease | Preclinical studies in progress | |||||||
|
MT-103 (MMT-205) |
IV(BsAb) | Tie2 / VEGF | Diabetic macular edema / Age-related Macular Degeneration |
Global licensing to Memento Medicines (May 2026). Preclinical studies in progress |
|
||||||
| MT-201 | IV(mAb) | Undisclosed | Thrombotic Diseases | Preclinical studies in progress | |||||||
| MT-202 | IV(BsAb) | Tie2 / Undisclosed | Thrombotic Diseases | Preclinical studies in progress | |||||||
Where We Aim to Innovate
Curacle addresses the common pathology of endothelial dysfunction, pioneering new treatment
paradigms across the eye, kidney, brain, cardiovascular, and inflammatory diseases.
paradigms across the eye, kidney, brain, cardiovascular, and inflammatory diseases.
Retinal diseases
Kidney diseases
Neurovascular disorders
Ischemic/Thrombotic diseases
Intractable inflammatory diseases